You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

CDX-1140

Showing 1 - 25 of 64
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Pancreatic Cancer, Cancer of the Pancreas, Pancreas Cancer Trial in Saint Louis (CDX-301, CDX-1140, Research blood draw)

Recruiting
  • Pancreatic Cancer
  • +2 more
  • Saint Louis, Missouri
    Washington University School of Medicine
Jan 17, 2023

Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma, Prognostic Stage IV Breast Cancer AJCC v8 Trial in Los

Recruiting
  • Anatomic Stage IV Breast Cancer AJCC v8
  • +5 more
  • Anti-CD40 Agonist Monoclonal Antibody CDX-1140
  • +3 more
  • Los Angeles, California
    USC/Norris Comprehensive Cancer Center
Jan 31, 2023

Biliary Cancer, Bile Duct Cancer, Cancer of the Bile Duct Trial run by the National Cancer Institute (NCI) (oxaliplatin,

Not yet recruiting
  • Biliary Cancer
  • +2 more
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
May 13, 2023

Ovarian Clear Cell Adenocarcinoma, Platinum-Sensitive Ovarian Carcinoma, Recurrent Endometrial Serous Adenocarcinoma Trial in

Not yet recruiting
  • Ovarian Clear Cell Adenocarcinoma
  • +14 more
  • Anti-CD40 Agonist Monoclonal Antibody CDX-1140
  • +4 more
  • Buffalo, New York
  • +1 more
Dec 16, 2022

Metastatic Pancreatic Adenocarcinoma Trial (odetiglucan, CDX-1140)

Not yet recruiting
  • Metastatic Pancreatic Adenocarcinoma
  • odetiglucan
  • CDX-1140
  • (no location specified)
Jul 29, 2022

Non Small Cell Lung Cancer, Lung Cancer Trial in Bronx (drug, biological, radiation)

Recruiting
  • Non Small Cell Lung Cancer
  • Lung Cancer
  • FLT3 Ligand (CDX-301)
  • +2 more
  • Bronx, New York
    Albert Einstein College of Medicine
Jul 18, 2022

Melanoma, NSCLC, Breast Cancer Trial in United States (CDX-1140, CDX-301, Pembrolizumab)

Completed
  • Melanoma
  • +25 more
  • CDX-1140
  • +3 more
  • Scottsdale, Arizona
  • +10 more
Sep 27, 2022

Metastatic Triple Negative Breast Cancer Trial in Dallas (PLD Chemotherapy, CDX-1140, CDX-301)

Recruiting
  • Metastatic Triple Negative Breast Cancer
  • PLD Chemotherapy
  • +2 more
  • Dallas, Texas
    UT Southwestern Medical Center
Jun 23, 2022

Malignant Epithelial Tumors Trial in Portland (TCR-transduced T cells, CDX-1140, Pembrolizumab)

Not yet recruiting
  • Malignant Epithelial Neoplasms
  • TCR-transduced T cells
  • +2 more
  • Portland, Oregon
    Providence Portland Medical Center
Apr 22, 2022

Exocrine Pancreatic Insufficiency Trial in Adelaide, Auckland, Christchurch (Part A, Part B, Part C)

Recruiting
  • Exocrine Pancreatic Insufficiency
  • Part A
  • +2 more
  • Adelaide, New South Wales, Australia
  • +3 more
Jan 12, 2023

Melanoma, Metastatic Melanoma Trial in Boston (CDX-301, NEOVAX, Nivolumab)

Recruiting
  • Melanoma
  • Metastatic Melanoma
  • Boston, Massachusetts
    Dana-Farber Cancer Institute
Jan 12, 2023

CNS Diseases Trial in Brisbane (Placebo, ALKS 1140)

Suspended
  • Central Nervous System Diseases
  • Placebo
  • ALKS 1140
  • Brisbane, Australia
    Alkermes Clinical Investigative Site
Feb 16, 2022

Chronic Spontaneous Urticaria Trial in Germany, United States (CDX-0159, Normal Saline)

Completed
  • Chronic Spontaneous Urticaria
  • Birmingham, Alabama
  • +13 more
Jan 24, 2023

Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma, Platinum-Resistant Primary Peritoneal

Active, not recruiting
  • Platinum-Resistant Fallopian Tube Carcinoma
  • +5 more
  • Tucson, Arizona
  • +16 more
Oct 19, 2022

Cold Urticaria, Cold Contact Urticaria, Symptomatic Dermographism Trial in Berlin (CDX-0159)

Active, not recruiting
  • Cold Urticaria
  • +4 more
  • Berlin, Germany
    Charite University
Dec 20, 2022

Prurigo Nodularis Trial in Germany, United States (CDX-0159, Normal saline)

Recruiting
  • Prurigo Nodularis
  • CDX-0159
  • Normal saline
  • Tempe, Arizona
  • +18 more
Jan 4, 2023

Glioma Trial (Blood sampling)

Not yet recruiting
  • Glioma
  • Blood sampling
  • (no location specified)
Oct 31, 2023

Chronic Spontaneous Urticaria Trial in Hungary, United States (barzolvolimab, Matching Placebo)

Recruiting
  • Chronic Spontaneous Urticaria
  • barzolvolimab
  • Matching Placebo
  • Birmingham, Alabama
  • +44 more
Dec 8, 2022

Chronic Inducible Urticaria Trial in United States (barzolvolimab, Matching Placebo)

Recruiting
  • Chronic Inducible Urticaria
  • barzolvolimab
  • Matching Placebo
  • Birmingham, Alabama
  • +31 more
Jan 20, 2023

Cutaneous Melanoma, Melanoma, Melanoma of Unknown Primary Trial in United States (DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Poly

Completed
Has Results
  • Cutaneous Melanoma
  • +11 more
  • DEC-205/NY-ESO-1 Fusion Protein CDX-1401
  • +2 more
  • Chicago, Illinois
  • +6 more
Nov 10, 2021

Metastatic Lung Cancer, Metastatic Gastrointestinal Cancer Trial (FoundationOne® Liquid CDx Assay, Standard of Care Diagnostic

Not yet recruiting
  • Metastatic Lung Cancer
  • Metastatic Gastrointestinal Cancer
  • FoundationOne® Liquid CDx Assay
  • Standard of Care Diagnostic Pathway
  • (no location specified)
May 11, 2023

Healthy Subjects Trial in Lincoln (CDX-0159, Normal saline)

Completed
  • Healthy Subjects
  • Lincoln, Nebraska
    Celerion, Inc
Jan 20, 2022

NSCLC, Gastric Cancer, Head Neck Cancer Trial (CDX-585)

Not yet recruiting
  • Non-small Cell Lung Cancer
  • +13 more
  • (no location specified)
Mar 29, 2023

Epithelial Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer Trial in Worldwide (Mirvetuximab Soravtansine, Paclitaxel,

Active, not recruiting
  • Epithelial Ovarian Cancer
  • +2 more
  • Mirvetuximab Soravtansine
  • +3 more
  • Birmingham, Alabama
  • +207 more
Oct 28, 2022

Metastatic Breast Cancer Trial in Rome (HER2-D is the use of a non-invasive liquid biopsy method to non-invasively and

Recruiting
  • Metastatic Breast Cancer
  • HER2-D is the use of a non-invasive liquid biopsy method to non-invasively and objectively assess HER2 status at recruitment
  • Rome, Italy
    Fondazione Policlinico A. Gemelli - IRCCS
Jun 22, 2023